Application of Flow Cytometry to Platelet Disorders

 

 Buy Article Permissions and Reprints

Flow cytometry is a powerful and versatile tool that can be used to yield definitive information regarding the phenotypic status of platelets. The method provides a quantitative assessment of the physical and antigenic properties of platelets (e.g., surface expression of receptors, bound ligands, components of granules, or interactions of platelets with other platelets, other blood cells, or components of the plasma coagulation system), thereby facilitating the diagnosis of inherited or acquired platelet disorders (e.g., Bernard-Soulier syndrome, Glanzmann thrombasthenia, storage pool disease), the pathological activation of platelets (e.g., in the setting of acute coronary syndromes, cerebrovascular ischemia, peripheral vascular disease, cardiopulmonary bypass), and changes in the ability of platelets to activate via specific stimuli (e.g., efficacy of antiplatelet therapies). Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care.

REFERENCES

• 1 Michelson A D, Barnard M R, Krueger L A et al.. Flow cytometry. In: Michelson AD Platelets San Diego, CA; Academic Press 2002: 297-315
  Google Scholar
• 2 Shapiro H M. Practical Flow Cytometry. 4th ed. New York; Wiley-Liss 2003
  Google Scholar
• 3 Michelson A D, Barnard M R, Hechtman H B et al.. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.  Proc Natl Acad Sci USA. 1996;  93 11877-11882
  CrossrefPubMedGoogle Scholar
• 4 Moritz A, Walcheck B K, Deye J, Weiss D J. Effects of short-term racing activity on platelet and neutrophil activation in dogs.  Am J Vet Res. 2003;  64 855-859
  PubMedGoogle Scholar
• 5 Boudreaux M K, Panangala V S, Bourne C. A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen.  Vet Pathol. 1996;  33 419-427
  PubMedGoogle Scholar
• 6 Michelson A D, Benoit S E, Kroll M H et al.. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible.  Blood. 1994;  83 3562-3573
  PubMedGoogle Scholar
• 7 Shattil S J, Hoxie J A, Cunningham M, Brass L F. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation.  J Biol Chem. 1985;  260 11107-11114
  PubMedGoogle Scholar
• 8 Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance.  Curr Opin Hematol. 1999;  6 342-348
  CrossrefPubMedGoogle Scholar
• 9 Barnard M R, Krueger L A, Frelinger A L et al.. Whole blood analysis of leukocyte-platelet aggregates. In: Robinson JP, Darzynkiewicz Z, Dean PN Current Protocols in Cytometry New York; John Wiley & Sons 2003 06.15.01-06: 15.08
  Google Scholar
• 10 Shattil S J, Cunningham M, Hoxie J A. Detection of activated platelets in whole blood using activation-dependant antibodies and flow cytometry.  Blood. 1987;  70 307-315
  CrossrefPubMedGoogle Scholar
• 11 Serebruany V L, Kereiakes D J, Dalesandro M R, Gurbel P A. The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges.  Thromb Res. 1999;  96 51-56
  CrossrefPubMedGoogle Scholar
• 12 Abrams C, Shattil S J. Immunological detection of activated platelets in clinical disorders.  Thromb Haemost. 1991;  65 467-473
  PubMedGoogle Scholar
• 13 Michelson A D. Flow cytometry: a clinical test of platelet function.  Blood. 1996;  87 4925-4936
  PubMedGoogle Scholar
• 14 Rajasekhar D, Barnard M R, Bednarek F J, Michelson A D. Platelet hyporeactivity in very low birth weight neonates.  Thromb Haemost. 1997;  77 1002-1007
  PubMedGoogle Scholar
• 15 Michelson A D, Barnard M R, Krueger L A et al.. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.  Circulation. 2001;  104 1533-1537
  CrossrefPubMedGoogle Scholar
• 16 Furman M I, Krueger L A, Frelinger III A L et al.. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.  Thromb Haemost. 2000;  84 492-498
  PubMedGoogle Scholar
• 17 Krueger L A, Barnard M R, Frelinger III A L et al.. Immunophenotypic analysis of platelets. In: Robinson JP, Darzynkiewicz Z, Dean PN Current Protocols in Cytometry. New York; John Wiley & Sons, Inc 2002: 06.10.01-06.10.17
  Google Scholar
• 18 Phillips D R, Teng W, Arfsten A et al.. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.  Circulation. 1997;  96 1488-1494
  CrossrefPubMedGoogle Scholar
• 19 Ginsberg M H, Lightsey A, Kunicki T J et al.. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb.  J Clin Invest. 1986;  78 1103-1111
  CrossrefPubMedGoogle Scholar
• 20 Kozek-Langenecker S A, Mohammad S F, Masaki T et al.. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry.  Anesth Analg. 2000;  90 808-812
  CrossrefPubMedGoogle Scholar
• 21 Filip D J, Aster R H. Relative hemostatic effectiveness of platelets stored at 4° and 22°C.  J Lab Clin Med. 1978;  91 618-624
  PubMedGoogle Scholar
• 22 Kuo Y R, Jeng S F, Wang F S et al.. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.  J Surg Res. 2002;  107 50-55
  PubMedGoogle Scholar
• 23 Furman M I, Kereiakes D J, Krueger L A et al.. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.  Am Heart J. 2003;  145
  PubMedGoogle Scholar
• 24 Furman M I, Kereiakes D J, Krueger L A et al.. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.  Am Heart J. 2001;  142 790-798
  CrossrefPubMedGoogle Scholar
• 25 Michelson A D, Barnard M R, Krueger L A et al.. Evaluation of platelet function by flow cytometry.  Methods. 2000;  21 259-270
  CrossrefPubMedGoogle Scholar
• 26 Wall J E, Buijs-Wilts M, Arnold J T et al.. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents.  Br J Haematol. 1995;  89 380-385
  CrossrefPubMedGoogle Scholar
• 27 Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired storage pool deficiency by flow cytometry.  Br J Haematol. 1995;  89 117-123
  CrossrefPubMedGoogle Scholar
• 28 Michelson A D. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia.  J Lab Clin Med. 1987;  110 346-354
  PubMedGoogle Scholar
• 29 Jennings L K, Ashmun R A, Wang W C, Dockter M E. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry.  Blood. 1986;  68 173-179
  CrossrefPubMedGoogle Scholar
• 30 Furman M I, Benoit S E, Barnard M R et al.. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.  J Am Coll Cardiol. 1998;  31 352-358
  CrossrefPubMedGoogle Scholar
• 31 Ott I, Neumann F J, Gawaz M et al.. Increased neutrophil-platelet adhesion in patients with unstable angina.  Circulation. 1996;  94 1239-1246
  PubMedGoogle Scholar
• 32 Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: A diagnostic aid in the evaluation of thrombocytopenic disorders.  Blood. 1990;  75 116-121
  CrossrefPubMedGoogle Scholar
• 33 Matic G B, Chapman E S, Zaiss M et al.. Whole blood analysis of reticulated platelets: improvements of detection and assay stability.  Cytometry. 1998;  34 229-234
  PubMedGoogle Scholar
• 34 Gawaz M, Seyfarth M, Muller I et al.. Comparisons of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent replacement.  Am J Cardiol. 2001;  87 332-336
  CrossrefPubMedGoogle Scholar
• 35 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
  CrossrefPubMedGoogle Scholar
• 36 Nurden A T, Nurden P. Inherited disorders of platelet function. In: Michelson AD Platelets San Diego; Academic Press 2002: 681-700
  Google Scholar
• 37 Lopez J A, Berndt M C. The GPIb-IX-V complex. In: Michelson AD Platelets San Diego; Academic Press 2002: 85-104
  Google Scholar
• 38 Rao A K, Gabbeta J. Congenital disorders of platelet signal transduction.  Arterioscl Thromb Vasc Biol. 2000;  20 285-289
  PubMedGoogle Scholar
• 39 Reed G L. Platelet secretion. In: Michelson AD Platelets San Diego; Academic Press 2002: 181-195
  Google Scholar
• 40 Gawaz M P, Bogner C, Gurland H J. Flow-cytometric analysis of mepacrine-labelled platelets in patients with end-stage renal failure.  Haemostasis. 1993;  23 284-292
  PubMedGoogle Scholar
• 41 Fabris F, Scandellari R, Randi M L et al.. Attempt to improve the diagnosis of immune thrombocytopenia by combined use of two different platelet autoantibodies assays (PAIgG and MACE).  Haematologica. 2002;  87 1046-1052
  PubMedGoogle Scholar
• 42 Lindahl T L, Fagerberg I H, Larsson A. A new flow cytometric method for measurement of von Willebrand factor activity.  Scand J Clin Lab Invest. 2003;  63 217-223
  CrossrefPubMedGoogle Scholar
• 43 Heeschen C, Hamm C W, Zeiher A M. Soluble CD40 ligand in acute coronary syndromes.  N Engl J Med. 2003;  348 1104-1111
  CrossrefPubMedGoogle Scholar
• 44 Kamath S, Blann A D, Caine G J et al.. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.  Stroke. 2002;  33 1237-1242
  CrossrefPubMedGoogle Scholar
• 45 Varo N, de Lemos J A, Libby P et al.. Soluble CD40L: Risk prediction after acute coronary syndromes.  Circulation. 2003;  108 1049-1052
  CrossrefPubMedGoogle Scholar
• 46 Michelson A D, Ellis P A, Barnard M R et al.. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound.  Blood. 1991;  77 770-779
  CrossrefPubMedGoogle Scholar
• 47 Faraday N, Goldschmidt-Clermont P, Dise K, Bray P F. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.  J Lab Clin Med. 1994;  123 728-740
  PubMedGoogle Scholar
• 48 Frelinger III A L, Lam S CT, Plow E F et al.. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion.  J Biol Chem. 1988;  263 12397-12402
  PubMedGoogle Scholar
• 49 Kouns W C, Kirchhofer D, Hadvary P et al.. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor.  Blood. 1992;  80 2539-2547
  PubMedGoogle Scholar
• 50 Zamarron C, Ginsberg M H, Plow E F. Monoclonal antibodies specific for a conformationally altered state of fibrinogen.  Thromb Haemost. 1990;  64 41-46
  PubMedGoogle Scholar
• 51 Heilmann E, Hynes L A, Burstein S A et al.. Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets.  Cytometry. 1994;  17 287-293
  CrossrefPubMedGoogle Scholar
• 52 McEver R P. P-Selectin/PSGL-1 and other interactions between platelets, leukocytes, and endothelium. In: Michelson AD Platelets San Diego; Academic Press 2002: 139-155
  Google Scholar
• 53 Hsu-Lin S C, Berman C L, Furie B C et al.. A platelet membrane protein expressed during platelet activation and secretion: studies using a monoclonal antibody specific for thrombin-activated platelets.  J Biol Chem. 1984;  259 9121-9126
  PubMedGoogle Scholar
• 54 Stenberg P E, McEver R P, Shuman M A et al.. A platelet alpha-granule membrane protein (GMP-140) is expressed on the platelet membrane after activation.  J Cell Biol. 1985;  101 880-886
  CrossrefPubMedGoogle Scholar
• 55 Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression.  Semin Thromb Hemost. 1995;  21 146-151
  PubMedGoogle Scholar
• 56 Metzelaar M J, Wijngaard P L, Peters P J et al.. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells.  J Biol Chem. 1991;  266 3239-3245
  PubMedGoogle Scholar
• 57 Furman M I, Barnard M R, Krueger L A et al.. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.  J Am Coll Cardiol. 2001;  38 1002-1006
  CrossrefPubMedGoogle Scholar
• 58 Peyton B D, Rohrer M J, Furman M I et al.. Patients with venous stasis ulceration have increased monocyte-platelet aggregation.  J Vasc Surg. 1998;  27 1109-1115
  PubMedGoogle Scholar
• 59 Sims P J, Faioni E M, Wiedmer T, Shattil S J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity.  J Biol Chem. 1988;  263 18205-18212
  PubMedGoogle Scholar
• 60 Nieuwland R, Sturk A. Platelet-derived microparticles. In: Michelson AD Platelets San Diego; Academic Press 2002: 255-265
  Google Scholar
• 61 Sims P J, Wiedmer T, Esmon C T et al.. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity.  J Biol Chem. 1989;  264 17049-17057
  PubMedGoogle Scholar
• 62 Michelson A D, Rajasekhar D, Bednarek F J, Barnard M R. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults.  Thromb Haemost. 2000;  84 689-694
  PubMedGoogle Scholar
• 63 Ault K A, Rinder H M, Mitchell J G et al.. Correlated measurement of platelet release and aggregation in whole blood.  Cytometry. 1989;  10 448-455
  PubMedGoogle Scholar
• 64 Flores N A, Sheridan D J. The pathophysiological role of platelets during myocardial ischaemia.  Cardiovasc Res. 1994;  28 295-302
  PubMedGoogle Scholar
• 65 Fuster V, Badimon L, Badimon J J, Chesebro J H. The pathogenesis of coronary artery disease and acute coronary syndromes.  N Engl J Med. 1992;  326 310-318
  CrossrefPubMedGoogle Scholar
• 66 deWood M A, Spores J, Notske R et al.. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.  N Engl J Med. 1980;  303 897-902
  CrossrefPubMedGoogle Scholar
• 67 Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
  PubMedGoogle Scholar
• 68 Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients.  BMJ. 1994;  308 235-246
  Google Scholar
• 69 Peripheral Arterial Diseases Antiplatelet Consensus Group . Antiplatelet therapy in peripheral arterial disease. Consensus statement.  Eur J Vasc Endovasc Surg. 2003;  26 1-16
  CrossrefPubMedGoogle Scholar
• 70 Mehta S R, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.  J Am Coll Cardiol. 2003;  41 79S-88S
  CrossrefPubMedGoogle Scholar
• 71 Koyama H, Maeno T, Fukumoto S et al.. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans.  Circulation. 2003;  108 524-529
  CrossrefPubMedGoogle Scholar
• 72 Coulter S A, Cannon C P, Ault K A et al.. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.  Circulation. 2000;  101 2690-2695
  CrossrefPubMedGoogle Scholar
• 73 Schultheiss H P, Tschoepe D, Esser J et al.. Large platelets continue to circulate in an activated states after myocardial infarction.  Eur J Clin Invest. 1994;  24 243-247
  CrossrefPubMedGoogle Scholar
• 74 Lee Y, Lee W H, Lee S C et al.. CD40L activation in circulating platelets in patients with acute coronary syndrome.  Cardiology. 1999;  92 11-16
  CrossrefPubMedGoogle Scholar
• 75 Scharf R E, Tomer A, Marzec U M et al.. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.  Arterioscl Thromb. 1992;  12 1475-1487
  PubMedGoogle Scholar
• 76 Gurbel P A, Kereiakes D J, Dalesandro M R et al.. Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department.  Am Heart J. 2000;  139 320-328
  PubMedGoogle Scholar
• 77 Langford E J, Wainwright R J, Martin J F. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.  Arterioscl Thromb Vasc Biol. 1996;  16 51-55
  PubMedGoogle Scholar
• 78 Ault K A, Cannon C P, Mitchell J G et al.. Platelet activation in patients after an acute coronary syndrome L results from the TIMI-12 trial. Thrombolysis in myocardial infarction.  J Am Coll Cardiol. 1999;  33 634-639
  CrossrefPubMedGoogle Scholar
• 79 Gawaz M, Neumann F J, Ott I et al.. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.  Circulation. 1996;  94 279-285
  CrossrefPubMedGoogle Scholar
• 80 Neumann F J, Gawaz M, Dickfeld T et al.. Antiplatelet effect of ticlopidine after coronary stenting.  J Am Coll Cardiol. 1997;  29 1515-1519
  CrossrefPubMedGoogle Scholar
• 81 Tschoepe D, Schultheiss H P, Kolarov P et al.. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.  Circulation. 1993;  88 37-42
  CrossrefPubMedGoogle Scholar
• 82 Ginsberg M H, Frelinger III A L, Lam S CT et al.. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies.  Blood. 1990;  76 2017-2023
  PubMedGoogle Scholar
• 83 Fateh-Moghadam S, Bocksch W, Ruf A et al.. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy.  Circulation. 2000;  102 890-897
  CrossrefPubMedGoogle Scholar
• 84 Mallat Z, Benamer H, Hugel B et al.. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.  Circulation. 2000;  101 841-843
  CrossrefPubMedGoogle Scholar
• 85 Vidal C, Spaulding C, Picard F et al.. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation.  Thromb Haemost. 2001;  86 784-790
  PubMedGoogle Scholar
• 86 Gawaz M, Reininger A, Neumann F J. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium.  Thromb Res. 1996;  83 341-349
  CrossrefPubMedGoogle Scholar
• 87 Neumann F J, Marx N, Gawaz M et al.. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets.  Circulation. 1997;  95 2387-2394
  CrossrefPubMedGoogle Scholar
• 88 Katopodis J N, Kolodny L, Jy W et al.. Platelet microparticles and calcium homeostasis in acute coronary ischemias.  Am J Hematol. 1997;  54 95-101
  CrossrefPubMedGoogle Scholar
• 89 Mickelson J K, Lakkis N M, Villarreal-Levy G et al.. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?.  J Am Coll Cardiol. 1996;  28 345-353
  PubMedGoogle Scholar
• 90 Grau A J, Ruf A, Vogt A et al.. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia.  Thromb Haemost. 1998;  80 298-301
  PubMedGoogle Scholar
• 91 Cherian P, Hankey G J, Eikelboom J W et al.. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes.  Stroke. 2003;  34 2132-2137
  CrossrefPubMedGoogle Scholar
• 92 Minamino T, Kitakaze M, Sanada S et al.. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide.  Circulation. 1998;  98 1721-1727
  CrossrefPubMedGoogle Scholar
• 93 Meiklejohn D J, Vickers M A, Morrison E R et al.. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib.  Br J Haematol. 2001;  112 621-631
  CrossrefPubMedGoogle Scholar
• 94 Zeiger F, Stephan S, Hoheisel G et al.. P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease.  Blood Coagul Fibrinolysis. 2000;  11 723-728
  CrossrefPubMedGoogle Scholar
• 95 Powell C C, Rohrer M J, Barnard M R et al.. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation.  J Vasc Surg. 1999;  30 844-851
  PubMedGoogle Scholar
• 96 Tschoepe D, Roesen P, Esser J et al.. Large platelets circulate in an active state in diabetes mellitus.  Semin Thromb Hemost. 1991;  17 433-438
  Article in Thieme ConnectPubMedGoogle Scholar
• 97 Tschoepe D, Menart-Houtermans B. Diabetes Mellitus. In: Michelson AD Platelets San Diego; Academic Press 2002: 435-445
  Google Scholar
• 98 Janes S L, Goodall A H. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy.  Clin Sci. 1994;  86 731-739
  CrossrefPubMedGoogle Scholar
• 99 Klein B, Farildi A, Amo-Takyi B K et al.. Neonatal platelet activation in preeclampsia.  Clin Appl Thromb Hemost. 2001;  7 29-32
  CrossrefPubMedGoogle Scholar
• 100 Kawabata K, Nakai S, Miwa M et al.. Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis.  Nephron. 2002;  90 391-400
  CrossrefPubMedGoogle Scholar
• 101 Ando M, Iwata A, Ozeki Y et al.. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients.  Kidney Int. 2002;  62 1757-1763
  CrossrefPubMedGoogle Scholar
• 102 Russworm S, Vickers J, Meier-Hellmann A et al.. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction.  Shock. 2002;  17 263-268
  PubMedGoogle Scholar
• 103 Joop K, Berckmans R J, Nieuwland R et al.. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms.  Thromb Haemost. 2001;  85 810-820
  PubMedGoogle Scholar
• 104 Villmow T, Kemkes-Matthes B, Matzdorff A C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.  Thromb Res. 2002;  108 139-145
  CrossrefPubMedGoogle Scholar
• 105 Sevush S, Jy W, Horstman L L et al.. Platelet activation in Alzheimer disease.  Arch Neurol. 1998;  55 530-536
  CrossrefPubMedGoogle Scholar
• 106 Zilla P, Fasol R, Groscurth P et al.. Blood platelets in cardiopulmonary bypass operations.  J Thorac Cardiovasc Surg. 1989;  97 379-388
  PubMedGoogle Scholar
• 107 Smith B R, Rinder H M, Rinder C S. Cardiopulmonary bypass. In: Michelson AD Platelets San Diego; Academic Press 2002: 27-741
  Google Scholar
• 108 Rinder C S, Gaal D, Student L A, Smith B R. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1994;  107 280-288
  PubMedGoogle Scholar
• 109 Harker L A, Malpass T W, Branson H E et al.. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha granule release.  Blood. 1980;  56 824-828
  PubMedGoogle Scholar
• 110 Michelson A D. The hemostatic defect of cardiopulmonary Bypass. In: Jones R, Elliott M Cardiopulmonary bypass in Neonates, Infants and Young Children. Oxford; Butterworth-Heinemann 1994
  Google Scholar
• 111 Warkentin T E, Chong B H, Greinacher A. Heparin induced thrombocytopenia: toward consensus.  Thromb Haemost. 1998;  79 1-7
  Article in Thieme ConnectPubMedGoogle Scholar
• 112 Wahba A, Rothe G, Lodes H et al.. Effect of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery.  Thromb Res. 2000;  97 379-386
  CrossrefPubMedGoogle Scholar
• 113 Ellison N, Edmunds L H, Colman R W. Platelet aggregation following heparin and protamine administration.  Anesthesiology. 1978;  48 65-68
  PubMedGoogle Scholar
• 114 Morse D S, Adams D, Magnani B. Platelet and neutrophil activation during cardiac surgical procedures: impact of cardiopulmonary bypass.  Ann Thorac Surg. 1998;  65 691-695
  CrossrefPubMedGoogle Scholar
• 115 Musial J, Niewiarowski S, Hershock D et al.. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation.  J Lab Clin Med. 1985;  105 514-522
  PubMedGoogle Scholar
• 116 Salzman E W, Lindon J, Brier D, Merrill E W. Surface-induced platelet adhesion, aggregation and release.  Ann N Y Acad Sci. 1977;  283 114-127
  PubMedGoogle Scholar
• 117 Wenger W K, Lukasiewicz H, Mikuta B S et al.. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1989;  97 235-239
  PubMedGoogle Scholar
• 118 Kestin A S, Valeri C R, Khuri S F et al.. The platelet function defect of cardiopulmonary bypass.  Blood. 1993;  82 107-117
  PubMedGoogle Scholar
• 119 Rinder C S, Mathew J, Rinder J et al.. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass.  Anesthesiology. 1991;  75 563-570
  PubMedGoogle Scholar
• 120 Khuri S F, Michelson A D, Valeri C R. The effects of cardiopulmonary bypass on hemostasis. In: Loscabo J, Schaferai AI Thrombosis & Hemorrhage Cambridge; Blackwell Science 1993: 1051-1073
  Google Scholar
• 121 Linden M D, Erber W N, Schneider M. Heparin management during cardiopulmonary bypass.  J Cardiovasc Surg. 2001;  42 431-433
  PubMedGoogle Scholar
• 122 Ng K FJ, Lam C CK, Chan L C. In vivo effect of haemodilution with saline on coagulation: a randomized controlled trial.  Br J Anaesth. 2002;  88 475-480
  CrossrefPubMedGoogle Scholar
• 123 Michelson A D, Macgregor H, Barnard M R et al.. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro.  Thromb Haemost. 1994;  71 633-640
  PubMedGoogle Scholar
• 124 Ferraris V A, Ferraris S P, Joseph O et al.. Aspirin and postoperative bleeding after coronary artery bypass grafting.  Ann Surg. 2002;  235 820-827
  CrossrefPubMedGoogle Scholar
• 125 Smith S C, Dove J T, Jacobs A K et al.. ACC/AHA guidelines intervention: Executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise The 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty).  Circulation. 2001;  104 3019-3043
  PubMedGoogle Scholar
• 126 Konstantopoulos K, Kamat S G, Schafer A I et al.. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment C7E3 Fab, in patients undergoing coronary angioplasty.  Circulation. 1995;  91 1427-1431
  PubMedGoogle Scholar
• 127 Gawaz M, Ruf A, Neumann F J et al.. Effect of glycoprotein IIB-IIIA receptor antagonism on platelet membrane glycoproteins after coronary stent placement.  Thromb Haemost. 1998;  80 994-1001
  PubMedGoogle Scholar
• 128 Quinn M, Deering A, Stewart M et al.. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antigens.  Circulation. 1999;  99 2231-2238
  PubMedGoogle Scholar
• 129 Hezard N, Metz D, Nazeyrollas P et al.. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA.  Thromb Haemost. 1999;  81 869-873
  PubMedGoogle Scholar
• 130 Tsao P W, Bozarth J M, Jackson S A et al.. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.  Thromb Res. 1995;  77 543-556
  CrossrefPubMedGoogle Scholar
• 131 Wittig K, Rothe G, Schmitz G. Inhibition of fibrinogen binding and surface recruitment of GPIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.  Thromb Haemost. 1998;  79 625-630
  PubMedGoogle Scholar
• 132 Peter K, Kohler B, Straub A et al.. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.  Circulation. 2000;  102 1490-1496
  PubMedGoogle Scholar
• 133 Jennings L K, White M M. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.  Am Heart J. 1998;  135 S179-S183
  PubMedGoogle Scholar
• 134 ISIS-2 Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2.  Lancet. 1998;  2 349-360
  PubMedGoogle Scholar
• 135 Lewis H D, Davis J W, Archibald D G et al.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina.  N Engl J Med. 1983;  309 396-403
  CrossrefPubMedGoogle Scholar
• 136 Malinin A I, Atar D, Callahan K P et al.. Effect of a single dose of aspirin on platelets in humans with multiple risk factors for coronary artery disease.  Eur J Pharmacol. 2003;  462 139-143
  CrossrefPubMedGoogle Scholar
• 137 Sane D C, McKee S A, Malinin A I, Serebruany V L. Frequency of aspirin resistance in patients with congestive heart failure with antecedant aspirin.  Am J Cardiol. 2002;  90 893-895
  CrossrefPubMedGoogle Scholar
• 138 Frelinger III A L, Marchese P J, Barnard M R et al.. Flow cytometric assessment of aspirin and NSAID effects on platelet function and leukocyte-platelet aggregation.  Blood. 2002;  100 704A
  CrossrefPubMedGoogle Scholar
• 139 Hollopeter G, Jantzen H-M, Vincent D et al.. Identification of the platelet ADP receptor targeted by antithrombotic drugs.  Nature. 2001;  409 202-207
  CrossrefPubMedGoogle Scholar
• 140 The CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
  CrossrefPubMedGoogle Scholar
• 141 Klinkhardt U, Bauersachs R, Adams J et al.. Clopidogrel but not aspirin reduced P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.  Clin Pharmacol Ther. 2003;  73 232-241
  CrossrefPubMedGoogle Scholar
• 142 Storey R F, Judge H M, Wilcox R G, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y 12 receptor antagonist AR-C69931MX but not aspirin.  Thromb Haemost. 2002;  88 488-494
  PubMedGoogle Scholar
• 143 Klinkhardt U, Graff J, Graff J. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model.  Clin Pharmacol Ther. 2002;  71 176-185
  CrossrefPubMedGoogle Scholar
• 144 Keha D, Thieme A, Kurer I et al.. Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine.  Blood Coagul Fibrinolysis. 2003;  14 327-334
  CrossrefPubMedGoogle Scholar
• 145 Kozek-Langenecker S A, Mohammad S F, Masaki T et al.. The effects of aprotinin on platelets in vitro using whole blood flow cytometry.  Anesth Analg. 2000;  90 12-16
  PubMedGoogle Scholar
• 146 Hu H, Hjemdahl P, Li N. Effects of insulin on platelet and leukocyte activity in whole blood.  Thromb Res. 2002;  107 209-215
  CrossrefPubMedGoogle Scholar
• 147 Murphy K J, Chronopoulos A K, Singh I et al.. Dietary Flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function.  Am J Clin Nutr. 2003;  77 1466-1473
  PubMedGoogle Scholar
• 148 Heesch C M, Wilhelm C R, Ristich J et al.. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans.  Heart. 2000;  83 688-695
  CrossrefPubMedGoogle Scholar
• 149 de Rossi L, Wessiepe M, Buhre W et al.. Effect of propofol on adhesion of activated platelets to leukocytes in human whole blood.  Intensive Care Med. 2003;  29 1157-1163
  CrossrefPubMedGoogle Scholar
• 150 Horn N A, de Rossi L, Robitzsch T et al.. The effects of sevoflurane and desflurane in vitro on platelet-leukocyte adhesion in whole blood.  Anaesthesia. 2003;  58 312-319
  CrossrefPubMedGoogle Scholar
• 151 Chong B H. Heparin-induced thrombocytopenia. In: Michelson AD Platelets San Diego; Academic Press 2002: 571-591
  Google Scholar
• 152 Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.  Br J Haematol. 1997;  98 648-656
  CrossrefPubMedGoogle Scholar
• 153 Romp K G, PeteRs W P, Hoffman M. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: an aid in assessing marrow recovery.  Am J Hematol. 1994;  46 319-324
  PubMedGoogle Scholar
• 154 Rinder H M, Schuster J E, Rinder C S et al.. Correlation of thrombosis with increased platelet turnover in thrombocytosis.  Blood. 1998;  91 1288-1294
  PubMedGoogle Scholar

Matthew D LindenPh.D. 

Room S5-853, Center for Platelet Function Studies, University of Massachusetts Medical School

55 Lake Avenue North

Worcester, MA 01655

Email: matthew.linden@umassmed.edu